EGFR and neoplasm: This result suggested that ARID1A expression loss could significantly alter the process of cell division by influencing the cell cycle of tumor cells in EGFR wild-type LUAD and activate a series of pathways, including the oncogenic MAPK pathway and ERBB2 pathway, to initiate and accelerate the development of the disease.